Assyro AI

FDA Orange Book · active-ingredient family

Magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate

Magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:SUFLAVE · NDA 215344

1

Brand (NDA)

0

Generics (ANDA)

4

Listed patents

1

Exclusivity periods

Brand (NDA) products · for solution

ProductApplicantApplicationTEApproved
SUFLAVERLDAZURITYNDA 215344Jun 15, 2023

Marketing exclusivity (1)

  • NPNew product exclusivity (3 years)

    Jun 15, 2026

    4 d ago

Listed patents (4)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
12433914Jun 14, 2044in 18 yr 3 mo
U-4143
12239659Jun 14, 2044in 18 yr 3 mo
U-4143
12594298Jun 14, 2044in 18 yr 3 mo
Product
12290529Aug 02, 2044in 18 yr 5 mo
Product

Magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.